73 related articles for article (PubMed ID: 9820067)
1. [Bezafibrate in the treatment of familial combined hyperlipidemia and its effect on certain parameters of lipid metabolism, particularly fibrinogen].
Urbánek R; Coufal Z
Vnitr Lek; 1998 May; 44(5):259-62. PubMed ID: 9820067
[TBL] [Abstract][Full Text] [Related]
2. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
[TBL] [Abstract][Full Text] [Related]
4. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
Vázquez-Chávez C; Salinas-Orozco S; Gómez-Díaz RA; Rosso-Juárez MM; Moreno-Vázquez K; Nissen-Torres T; Argüero-Sánchez R
Rev Invest Clin; 1998; 50(6):491-6. PubMed ID: 10070221
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Avisar I; Brook JG; Wolfovitz E
Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L
Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993
[TBL] [Abstract][Full Text] [Related]
7. [Present status of fibrates in the treatment of hyperlipoproteinemias].
Soska V
Vnitr Lek; 1999 Jul; 45(7):438-40. PubMed ID: 11045165
[TBL] [Abstract][Full Text] [Related]
8. [Etophylline clofibrate in the treatment of familial combined hyperlipoproteinemia].
Raslová K; Hucková M
Vnitr Lek; 1995 Apr; 41(4):240-2. PubMed ID: 7762188
[TBL] [Abstract][Full Text] [Related]
9. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Yesilbursa D; Serdar A; Saltan Y; Serdar Z; Heper Y; Guclu S; Cordan J
Kardiol Pol; 2005 Jun; 62(6):526-30. PubMed ID: 16123850
[TBL] [Abstract][Full Text] [Related]
10. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Blanco-Colio LM; Martín-Ventura JL; Sol JM; Díaz C; Hernández G; Egido J
J Am Coll Cardiol; 2004 Apr; 43(7):1188-94. PubMed ID: 15063428
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
[TBL] [Abstract][Full Text] [Related]
12. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
13. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
16. [Bezalip in the treatment of hyperlipoproteinemia].
Ceska R; Sobra J; Procházková P; Kvasilová M
Cas Lek Cesk; 1990 Jan; 129(1):20-2. PubMed ID: 2331712
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.
Lakatos J; Molnár M; Tóth K
Acta Physiol Hung; 1996; 84(4):433-5. PubMed ID: 9328624
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
19. [Effects of bezafibrate in patients with combined hyperlipidemia].
Vílchez Joya R; Escobar Jiménez F; Campos MM; Torres E; Orduña R; Cabrera J; Núñez J
Med Clin (Barc); 1986 Feb; 86(5):190-4. PubMed ID: 3959651
[No Abstract] [Full Text] [Related]
20. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.
Fujita N; Kaito M; Kai M; Sugimoto R; Tanaka H; Horiike S; Konishi M; Iwasa M; Watanabe S; Adachi Y
J Viral Hepat; 2006 Jul; 13(7):441-8. PubMed ID: 16792537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
